Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Revenue projections:

Revenue projections for INCY
Revenue projections for INCY

INCY's revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.

Financial Ratios:

currentRatio 3.316000
forwardPE 11.528706
debtToEquity 1.063000
earningsGrowth 0.436000
revenueGrowth 0.278000
grossMargins 0.528850
operatingMargins 0.255720
trailingEps 6.410000
forwardEps 8.677470

With a current ratio of 3.316, INCY has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that INCY is in a strong position to meet its immediate financial obligations without difficulty.
INCY's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
INCY's positive earnings and revenue growth indicate that the company is on track to expand its business. This growth suggests a strong financial outlook, with increasing profits and sales positioning INCY for continued success in the market.
With positive gross and operating margins, INCY demonstrates strong profitability. This reflects the company's ability to manage costs and maintain healthy profits, showcasing effective operational efficiency and financial stability.
INCY's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting INCY to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for INCY
Price projections for INCY

INCY's price projections have been consistently revised upward, suggesting that analysts are becoming increasingly optimistic about the company's future. This trend reflects confidence in INCY's ability to achieve strong financial results.

Insider Transactions:

Insider Transactions for INCY
Insider Transactions for INCY


There were 31 INCY sales transactions, at market price of 86.37290339316091.Throughout the period under consideration, no sell transactions were recorded.More buys than sells near the current price levels of Incyte Corporation might signal a favorable outlook for the stock. Investors seem to be showing confidence by purchasing more, potentially expecting positive future performance.

Recommendation changes over time:

Recommendations trend for INCY
Recommendations trend for INCY


Analysts have shown a buy bias for INCY, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to INCY, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.